The results of the Evidence for Contraceptive Options and HIV Outcomes, (ECHO) StudyExit Disclaimer — which ran from December 2015 through October 2018 — were announced recently at the South African AIDS Conference in Durban.
The ECHO Study compared the risk of HIV acquisition among women randomized to using three common methods of contraception: progestin-only depot-medroxyprogesterone acetate, given by intramuscular injection (DMPA-IM); a non-hormonal copper intrauterine device (copper IUD); and a progestin-based implant containing the hormone levonorgestrel (LNG implant).
The United States Agency for International Development (USAID) was among the multiple funders of the trial.
Read the study news releaseExit Disclaimer [PDF, 193KB].
Read the study summary alert from The LancetExit Disclaimer.
Read the findings published in The LancetExit Disclaimer.